Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AFFX's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

AFFX Guru Trades in Q3 2015

Steven Cohen 323,600 sh (New)
Ken Fisher 352,394 sh (New)
Joel Greenblatt 49,493 sh (New)
Jim Simons 2,463,923 sh (+14.41%)
Chuck Royce 4,000 sh (unchged)
Murray Stahl 104,000 sh (unchged)
PRIMECAP Management 10,856,540 sh (-1.44%)
Paul Tudor Jones 25,100 sh (-18.24%)
» More
Q4 2015

AFFX Guru Trades in Q4 2015

Ken Fisher 379,737 sh (+7.76%)
PRIMECAP Management 10,897,740 sh (+0.38%)
Murray Stahl 104,000 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones Sold Out
Chuck Royce Sold Out
Jim Simons 2,246,623 sh (-8.82%)
Steven Cohen 128,000 sh (-60.44%)
» More
Q1 2016

AFFX Guru Trades in Q1 2016

Steven Cohen 595,000 sh (+364.84%)
Jim Simons 2,987,399 sh (+32.97%)
Murray Stahl 104,000 sh (unchged)
Ken Fisher Sold Out
PRIMECAP Management 10,544,194 sh (-3.24%)
» More
Q2 2016

AFFX Guru Trades in Q2 2016

Jim Simons Sold Out
PRIMECAP Management Sold Out
Steven Cohen Sold Out
Murray Stahl Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AFFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research  
Compare:SZSE:300685, NAS:ABAX, NAS:GHDX, NAS:AXDX, SZSE:300439, NAS:KANG, NAS:ALOG, BSP:PARD3, SHSE:600055, NAS:NRCIA, NAS:VREX, NAS:BEAT, NSE:LALPATHLAB, TSE:4694, SZSE:300396, NAS:MEDP, SHSE:603108, HKSE:02393, TSE:4282, NAS:QDEL » details
Traded in other countries:AFF.Germany,
Headquarter Location:USA
Affymetrix Inc provides life science products and molecular diagnostic products that enables parallel analysis of biological systems at the gene, protein and cell level.

Affymetrix Inc was incorporated in California in 1992 and reincorporated in Delaware in 1998. The Company is a provider of life science tools and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. It sells its products to genomic research centers, academic institutions, government and private laboratories, as well as pharmaceutical, diagnostic and biotechnology companies. The Companys operations consist of two reportable segments, Affymetrix Core and eBioscience. Affymetrix Core is divided into three business units with each business unit having its own research, development and marketing groups to better serve customers and respond quickly to the market needs. The three business units that form Affymetrix Core are; Expression, Genetic Analysis and Clinical Applications, and Life Science Reagents. Expression: This business unit develops and markets the Company's GeneChip gene expression products and services, and the QuantiGene line of low-to-mid-plex RNA measurement products; Genetic Analysis and Clinical Applications. This business unit develops and markets the Company's genotyping, such as the Axiom product line and clinical research applications, such as the CytoScan cytogenetics; Life Science Reagents; This business unit develops and sells reagents, enzymes, purification kits and biochemicals used by life science researchers. eBioscience; This reportable segment specializes in the development, manufacturing, marketing and distribution of research tools in the areas of flow cytometry, immunoassays, microscopic imaging and other protein-based analyses. The Company markets and distributes its products directly to customers in North America, Japan and major European markets. The Company is facing competition as existing companies develop new or improved products, and as companies enter the market with new technologies, such as next-generation sequencing. In the highly multiplexed genotyping and gene expression markets, existing competitive technologies include DNA sequencing, which the Company does not offer and is offered by companies such as Illumina, Inc., Life Technologies Corporation and Pacific Biosciences of California, Inc. The Companys operations are subject to complex and stringent environmental, health, safety and other governmental laws and regulations.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $359.79
EPS (TTM) $ 0.12
Short Percentage of Float17.83%
52-Week Range $8.28 - 16.15
Shares Outstanding (Mil)80.54

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 375 389 404
EPS ($) 0.43 0.46 0.50
EPS without NRI ($) 0.43 0.46 0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: ----
Positive ROAN
Positive CFROAN
Higher ROA yoyN
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyN
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}